PFMU
TARA icon

Privium Fund Management (UK)’s Protara Therapeutics TARA Stock Holding History

Privium Fund Management (UK)’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-114,708
Closed -$233K – 132
2024
Q2 		$233K Sell
114,708
-5,022
-4% -$14.7K 0.09% 144
2024
Q1 		$496K Hold
119,730
– – 0.25% 60
2023
Q4 		$225K Hold
119,730
– – 0.15% 66
2023
Q3 		$201K Hold
119,730
– – 0.16% 65
2023
Q2 		$272K Hold
119,730
– – 0.21% 57
2023
Q1 		$401K Hold
119,730
– – 0.32% 51
2022
Q4 		$321K Buy
119,730
+84,730
+242% +$267K 0.24% 41
2022
Q3 		$104K Buy
+35,000
New +$119K 0.13% 50

Other funds holding TARA

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Privium Fund Management (UK)'s TARA Position: Q3 2024 in Review

Privium Fund Management (UK) sold out of Protara Therapeutics (TARA) in Q3 2024, closing a stake of 114,708 shares — an estimated $233K sold.

Privium Fund Management (UK) first reported a position in TARA in Q3 2022 and held it in 8 quarters. The position peaked at $496K in Q1 2024. 35 funds tracked by Wall St. Rank hold TARA as of Q3 2024.

  • Privium Fund Management (UK) reported no remaining Protara Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Privium Fund Management (UK) sold 114,708 Protara Therapeutics shares in Q3 2024, an estimated $233K.
  • Privium Fund Management (UK) first reported a position in Protara Therapeutics in Q3 2022 and held it in 8 quarters.
  • Privium Fund Management (UK)'s Protara Therapeutics position peaked at $496K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Protara Therapeutics as of Q3 2024.

Based on Privium Fund Management (UK)'s 13F filing for Q3 2024, filed 5 Nov 2024.